Compound Information | SONAR Target prediction | Name: | CLINDAMYCIN HYDROCHLORIDE | Unique Identifier: | SPE01500193 | MolClass: | Checkout models in ver1.5 and ver1.0 | Molecular Formula: | | Molecular Weight: | 427.174 g/mol | X log p: | 0.00899999999999979 (online calculus) | Lipinksi Failures | 0 | TPSA | 54.84 | Hydrogen Bond Donor Count: | 0 | Hydrogen Bond Acceptors Count: | 7 | Rotatable Bond Count: | 8 | Canonical Smiles: | Cl.CCCC1CC(N(C)C1)C(=O)NC(C(C)Cl)C1OC(SC)C(O)C(O)C1O | Source: | semisynthetic; U-21251 | Therapeutics: | antibacterial, inhibits protein synthesis | Generic_name: | Clindamycin | Chemical_iupac_name: | N-[2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-tetrahydropyran-2-yl)-propyl]-1-met hyl-4-propyl-pyrrolidine-2-carboxamide | Drug_type: | Approved Drug | Pharmgkb_id: | PA449035 | Kegg_compound_id: | C06914 | Drugbank_id: | APRD00566 | Melting_point: | 255 oC | H2o_solubility: | 30.6 mg/L | Logp: | 1.224 | Cas_registry_number: | 18323-44-9 | Drug_category: | Anti-bacterial Agents; Lincomycins; ATC:D10AF01; ATC:G01AA10; ATC:J01FF01 | Indication: | For the treatment of serious infections caused by susceptible anaerobic bacteria (anaerobes, streptococci, pneumococci, and staphylococci) | Pharmacology: | Clindamycin is an antibiotic, similar to and a derivative of lincomycin. Clindamycin can be used in topical or systemic treatment. It is effective as an anti-anaerobic antibiotic and antiprotozoal. | Mechanism_of_action: | Systemic/Vaginal-Clindamycin inhibits protein synthesis of bacteria by binding to the 50 S ribosomal subunits of the bacteria. Topical-Clindamycin reduces free fatty acid concentrations on the skin and to suppress the growth of Propionibacterium acnes (Corynebacterium acnes) , an anaerobe found in sebaceous glands and follicles. | Organisms_affected: | Enteric bacteria and other eubacteria |
Species: |
4932 |
Condition: |
REF2 |
Replicates: |
2 |
Raw OD Value: r im |
0.3309±0.0173948 |
Normalized OD Score: sc h |
0.9404±0.00104412 |
Z-Score: |
-1.7265±0.0157902 |
p-Value: |
0.084273 |
Z-Factor: |
-1.15672 |
Fitness Defect: |
2.4737 |
Bioactivity Statement: |
Nonactive |
Experimental Conditions | | Library: | SPECMTS3 | Plate Number and Position: | 3|F2 | Drug Concentration: | 50.00 nM | OD Absorbance: | 600 nm | Robot Temperature: | 26.50 Celcius | Date: | 2008-08-27 YYYY-MM-DD | Plate CH Control (+): | 0.04165±0.00084 | Plate DMSO Control (-): | 0.332175±0.01561 | Plate Z-Factor: | 0.8715 |
| png ps pdf |
3000512 |
(2S)-N-[2-chloro-1-[(3S,6R)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrol idine-2-carboxamide |
3032758 |
(2R)-N-[(2S)-2-chloro-1-[(3S,6R)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-methyl-4-propyl-p yrrolidine-2-carboxamide |
3034218 |
(2S,4R)-N-[(1S,2R)-2-chloro-1-[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-me thyl-4-propyl-pyrrolidine-2-carboxamide |
3629486 |
N-[2-chloro-1-(3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl)propyl]-1-methyl-4-propyl-2,3,4,5-tetrahydrop yrrole-2-carboxamide |
5481342 |
(2S,4R)-N-[(2S)-2-chloro-1-[(2S)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-methyl-4-propyl-p yrrolidine-2-carboxamide |
5702025 |
(2S,4R)-N-[2-chloro-1-[(3S,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-methyl-4-prop yl-pyrrolidine-2-carboxamide hydrochloride |
internal high similarity DBLink | Rows returned: 0 | |
active | Cluster 915 | Additional Members: 6 | Rows returned: 0 | |
|